Sign In
Buy NVRO
$5.84
+0 (+0%)
At Close: Jul 01, 2025
Why Nevro Stock Lagged the Market on Thursday
06:21pm, Thursday, 22'nd Feb 2024
Despite convincing beats on its latest set of quarterly figures, the market wasn't all that impressed with the company's latest developments.
Nevro's (NVRO) Q4 Earnings and Sales Top Estimates, Margins Up
11:51am, Thursday, 22'nd Feb 2024
Nevro's (NVRO) fourth-quarter earnings and revenues surpass their respective consensus estimate. The company incurs a loss in the operating level.
Nevro Corp. (NVRO) Q4 2023 Earnings Call Transcript
11:02pm, Wednesday, 21'st Feb 2024
Nevro Corp. (NVRO) Q4 2023 Earnings Call Transcript
Nevro (NVRO) Reports Q4 Loss, Tops Revenue Estimates
06:21pm, Wednesday, 21'st Feb 2024
Nevro (NVRO) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.54 per share a year ago.
Nevro Enters Into Cooperation Agreement With Engaged Capital
04:06pm, Wednesday, 21'st Feb 2024
Appoints Kirt P. Karros to Board of Directors REDWOOD CITY, Calif.
Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results
04:05pm, Wednesday, 21'st Feb 2024
Provides Full-Year and First-Quarter 2024 Guidance REDWOOD CITY, Calif. , Feb. 21, 2024 /PRNewswire/ --Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-
Will Nevro (NVRO) Report Negative Earnings Next Week? What You Should Know
11:06am, Wednesday, 14'th Feb 2024
Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Experts in diabetes, pain and health services from the Worldwide Initiative for Diabetes Education recommend spinal cord stimulation when symptoms aren't responsive to first- or second-line therapies
Nevro to Report Fourth-Quarter and Full-Year 2023 Financial Results and Host Conference Call on February 21, 2024
04:30pm, Monday, 29'th Jan 2024
REDWOOD CITY, Calif. , Jan. 29, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pa
Nevro's (NVRO) SCS Therapy Gets Positive Coverage Update
11:51am, Friday, 19'th Jan 2024
Nevro's (NVRO) latest announcement of a positive coverage update from Carelon Healthcare for PDN treatment is likely to serve a wider patient pool.
Nevro Announces Positive Coverage Update from Carelon Healthcare for the Treatment of Painful Diabetic Neuropathy
04:15pm, Thursday, 18'th Jan 2024
Spinal Cord Stimulation Coverage Policy to Include 43 Million Additional Covered Lives REDWOOD CITY, Calif. , Jan. 18, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company t
Nevro's (NVRO) Preliminary Q4 Revenues Boosted by PDN Sales
11:19am, Wednesday, 10'th Jan 2024
Nevro's (NVRO) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its PDN business.
Nevro laying off 63 employees; revenue to beat analyst estimates
08:50am, Tuesday, 09'th Jan 2024
Nevro Corp.'s stock NVRO, +5.27% rose by 0.3% in premarket trades on Tuesday after the Redwood City, Calif.-based medical device maker said it would reduce its work force by 5% or 63 people.
Nevro to Present at 42nd Annual J.P. Morgan Healthcare Conference
04:15pm, Thursday, 04'th Jan 2024
REDWOOD CITY, Calif. , Jan. 4, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pa
3 Reasons to Retain Nevro (NVRO) in Your Portfolio for Now
12:46pm, Tuesday, 26'th Dec 2023
Investors continue to be optimistic about Nevro (NVRO) due to its R&D edge.
